CN111094253B - 1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮类似物 - Google Patents

1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮类似物 Download PDF

Info

Publication number
CN111094253B
CN111094253B CN201880059242.4A CN201880059242A CN111094253B CN 111094253 B CN111094253 B CN 111094253B CN 201880059242 A CN201880059242 A CN 201880059242A CN 111094253 B CN111094253 B CN 111094253B
Authority
CN
China
Prior art keywords
ring
cancer
optionally substituted
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880059242.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN111094253A (zh
Inventor
黄琴华
布伦特·克莱顿·博伦
凯文·杜安·邦克
刘辉
苏尼尔·帕里瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ricoram Ip Holding Co ltd
Original Assignee
Ricoram Ip Holding Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ricoram Ip Holding Co ltd filed Critical Ricoram Ip Holding Co ltd
Publication of CN111094253A publication Critical patent/CN111094253A/zh
Application granted granted Critical
Publication of CN111094253B publication Critical patent/CN111094253B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201880059242.4A 2017-08-01 2018-07-31 1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮类似物 Active CN111094253B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539734P 2017-08-01 2017-08-01
US62/539,734 2017-08-01
PCT/US2018/044580 WO2019028008A1 (en) 2017-08-01 2018-07-31 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES

Publications (2)

Publication Number Publication Date
CN111094253A CN111094253A (zh) 2020-05-01
CN111094253B true CN111094253B (zh) 2023-08-29

Family

ID=65233095

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880059242.4A Active CN111094253B (zh) 2017-08-01 2018-07-31 1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮类似物

Country Status (16)

Country Link
US (2) US11124518B2 (enExample)
EP (1) EP3661918B1 (enExample)
JP (1) JP7203816B2 (enExample)
KR (1) KR20200034781A (enExample)
CN (1) CN111094253B (enExample)
AR (1) AR112774A1 (enExample)
AU (1) AU2018312448B2 (enExample)
BR (1) BR112020002104A2 (enExample)
CA (1) CA3071405A1 (enExample)
ES (1) ES2980537T3 (enExample)
IL (1) IL272262A (enExample)
MX (1) MX2020001235A (enExample)
RU (1) RU2020105058A (enExample)
SG (1) SG11202000789WA (enExample)
TW (1) TW201910335A (enExample)
WO (1) WO2019028008A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3078945A1 (en) 2017-10-09 2019-04-18 Nuvation Bo Inc. Heterocyclic compounds and uses thereof
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
AU2019227823B2 (en) * 2018-02-28 2024-12-12 The Regents Of The University Of Colorado, A Body Corporate WEE1 kinase inhibitors and methods of treating cancer using the same
PL3762385T3 (pl) * 2018-03-09 2025-06-23 Recurium Ip Holdings, Llc Podstawione 1,2-dihydro-3h-pirazolo[3,4-d]pirymidyn-3-ony
CN110872296B (zh) * 2018-08-31 2023-05-23 上海弘翊生物科技有限公司 一种二氢异吲哚-1H-吡唑并[3,4-d]嘧啶酮化合物、其制备方法和应用
US20220220115A1 (en) * 2019-04-09 2022-07-14 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
AU2020271837A1 (en) * 2019-04-09 2021-11-18 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210381A1 (en) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
US20220259210A1 (en) 2019-06-28 2022-08-18 Shanghai Pharmaceuticals Holding Co., Ltd. Pyrazolone-Fused Pyrimidine Compound, Preparation Method for Same and Applications Thereof
CN112142748B (zh) * 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN112442049A (zh) * 2019-09-03 2021-03-05 微境生物医药科技(上海)有限公司 作为Wee1抑制剂的嘧啶衍生物
IL292920A (en) 2019-11-15 2022-07-01 Recurium Ip Holdings Llc Chiral synthesis of tertiary alcohol
AU2020407070A1 (en) * 2019-12-20 2022-07-14 Recurium Ip Holdings, Llc Combinations
MX2022014131A (es) * 2020-05-15 2023-01-05 Recurium Ip Holdings Llc Monoterapias y terapias de combinacion.
CA3180664A1 (en) * 2020-06-17 2021-12-23 Yuli Xie Pyrazolo[3,4-d]pyrimidine-3-one derivative as wee-1 inhibitor
CN114805357B (zh) * 2021-01-21 2023-12-19 四川大学 一种靶向setdb1-ttd的小分子抑制剂及其制药用途
US20240182482A1 (en) * 2021-04-30 2024-06-06 Wigen Biomedicine Technology (shanghai) Co., Ltd. Fused cyclic compound as wee-1 inhibitor, preparation method therefor and use thereof
CN117751122A (zh) * 2021-08-11 2024-03-22 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
CN117940430B (zh) * 2021-09-22 2025-10-31 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
WO2023166080A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074985A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
CN101432284A (zh) * 2006-04-27 2009-05-13 万有制药株式会社 二氢吡唑并嘧啶酮衍生物
EP2213673A1 (en) * 2007-10-23 2010-08-04 Banyu Pharmaceutical Co., Ltd. Pyridone-substituted-dihydropyrazolopyrimidinone derivative

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1211942A1 (en) * 2012-09-10 2016-06-03 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
GB201612092D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074985A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
CN101432284A (zh) * 2006-04-27 2009-05-13 万有制药株式会社 二氢吡唑并嘧啶酮衍生物
EP2213673A1 (en) * 2007-10-23 2010-08-04 Banyu Pharmaceutical Co., Ltd. Pyridone-substituted-dihydropyrazolopyrimidinone derivative

Also Published As

Publication number Publication date
WO2019028008A1 (en) 2019-02-07
KR20200034781A (ko) 2020-03-31
MX2020001235A (es) 2020-07-20
US11124518B2 (en) 2021-09-21
AU2018312448B2 (en) 2022-09-15
AR112774A1 (es) 2019-12-11
US20210317124A1 (en) 2021-10-14
BR112020002104A2 (pt) 2020-08-04
US20200157112A1 (en) 2020-05-21
EP3661918A4 (en) 2021-05-12
EP3661918A1 (en) 2020-06-10
ES2980537T3 (es) 2024-10-01
AU2018312448A1 (en) 2020-02-13
CA3071405A1 (en) 2019-02-07
RU2020105058A3 (enExample) 2021-11-17
RU2020105058A (ru) 2021-09-02
CN111094253A (zh) 2020-05-01
TW201910335A (zh) 2019-03-16
EP3661918B1 (en) 2024-05-08
JP2020529993A (ja) 2020-10-15
EP3661918C0 (en) 2024-05-08
SG11202000789WA (en) 2020-02-27
JP7203816B2 (ja) 2023-01-13
IL272262A (en) 2020-03-31

Similar Documents

Publication Publication Date Title
CN111094253B (zh) 1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮类似物
JP7726563B2 (ja) 置換１，２－ジヒドロ－３Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－３－オン
WO2023049691A1 (en) Cdk7 inhibitors and methods of treating cancer
KR20220133874A (ko) 매크로사이클릭 화합물
RU2847224C2 (ru) Замещенные 1,2-дигидро-3н-пиразоло[3,4-d]пиримидин-3-оны
RU2812726C2 (ru) Замещенные 1,2-дигидро-3н-пиразоло[3,4-d]пиримидин-3-оны
HK40043303A (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
HK40043303B (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant